A new global study published in JAMA Network Open links the antibiotic cefepime to a higher risk of death compared to other beta-lactam antibiotics like penicillins and cephalosporins. The research, which analyzed 110 randomized clinical trials involving over 22,000 patients, found that 6.6% of those given cefepime died within about 30 days, compared to 6.2% for other antibiotics. A Bayesian meta-analysis indicated a 94.4% probability that cefepime is associated with higher all-cause mortality, rising to 98.6% when considering peer-reviewed trials only. The study highlights the need for further research and better dosing guidance due to potential toxic side effects of cefepime.
Written by the local model on 2026-09-16,
using this article's own text rather than the other coverage of the
same event (that is the story summary below).
A commonly used drug has been linked to a higher risk of death in a new study.
asserted
drug → use → study
The antibiotic, cefepime, which is used to treat bacterial infections like pneumonia, UTIs, and skin infections, is typically administered via injection by healthcare providers in a clinical setting.
asserted
which → use → setting
Severe side effects may include confusion, decreased consciousness, or seizures, especially in older patients and those with kidney problems, among many other common symptoms, according to Mayo Clinic.
uncertain
effects → include → Clinic
New research suggests the medication may be associated with a higher risk of all-cause mortality.
uncertain
medication → suggest → mortality
The new global study, published in JAMA Network Open, reviewed 110 randomized clinical trials involving more than 22,000 patients who received cefepime or another beta-lactam antibiotic — a class of drugs that includes penicillins and cephalosporins.
asserted
that → publish → penicillins
The patients included adults and children treated for febrile neutropenia — a medical emergency involving fever and dangerously low infection-fighting white blood cells — as well as pneumonia, severe bacterial infections, UTIs, and meningitis.
asserted
patients → include → fever
Across all trials, 778 deaths occurred among 11,726 patients (6.6%) given cefepime, compared to 6.2% of patients given another antibiotic.
asserted
deaths → occur → antibiotic
Researchers evaluated deaths from any cause occurring within about 30 days of treatment.
asserted
Researchers → evaluate → treatment
Using a Bayesian meta-analysis, the researchers found a 94.4% probability that cefepime was associated with higher all-cause mortality compared with other beta-lactam antibiotics.
asserted
cefepime → use → antibiotics
When the analysis was limited to 73 peer-reviewed published trials, that probability increased to 98.6%.
asserted
probability → limit → %
The association appeared stronger in adults than in children, and was most pronounced among patients treated for febrile neutropenia.
asserted
association → appear → neutropenia
Cefepime remains a commonly used broad-spectrum antibiotic for treating serious bacterial infections in hospitalized patients because it is effective against a wide range of bacteria.
asserted
it → remain → bacteria
The researchers did not recommend discontinuing cefepime, but called for additional guidance and research to better understand its safety.
asserted
researchers → recommend → safety
Start your day with all you need to know
Morning Report delivers the latest news, videos, photos and more.
asserted
Report → start → news
The researchers said several factors could potentially explain the observed association between cefepime and higher mortality, although they were unable to identify a single cause.
uncertain
they → say → cause
Possible explanations include drug levels that are too low to effectively treat the infection and neurotoxicity, which can occur when drug levels become too high.
asserted
levels → include → infection
Researchers said finding the right dose of cefepime can be challenging, as higher doses may improve its ability to kill bacteria while also increasing the risk of toxic side effects.
uncertain
doses → say → effects
The study had several limitations.
asserted
study → have → limitations
It combined clinical trials that differed in design, patient populations, dosing strategies and comparison antibiotics, with some studies dating back decades.
asserted
that → combine → studies
The analysis also found an association, not proof that cefepime itself caused the higher mortality.
asserted
cefepime → find → mortality
Dr. Marc Siegel, Fox News senior medical analyst, said the study demonstrates the importance of re-reviewing and analyzing older studies.
asserted
study → say → studies
“In this case, it correctly pointed out that febrile neutropenia (low white blood cell count with a fever) is itself a big cause of death in this population, making it often difficult to determine if the treatment (cefepime) decreases or possibly increases this risk,” Siegel, who was not involved in the research, told Fox News Digital.
uncertain
who → point → Digital
A closer review of the data suggests that both underdosing and overdosing — rather than the drug itself — may be more closely linked to poorer outcomes and a higher risk of death, indicating that appropriate dosing may be the key, according to the doctor.
uncertain
dosing → suggest → doctor
“I also think there may be a role for AI here in determining the exact right dose, as well as assessing outcome,” Siegel suggested.
uncertain
Siegel → think → outcome
The Aporia
